OnabotulinumtoxinA + KYBELLA
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Facial Contouring
Conditions
Facial Contouring
Trial Timeline
Jan 16, 2025 → Mar 1, 2026
NCT ID
NCT06783621About OnabotulinumtoxinA + KYBELLA
OnabotulinumtoxinA + KYBELLA is a approved stage product being developed by AbbVie for Facial Contouring. The current trial status is active. This product is registered under clinical trial identifier NCT06783621. Target conditions include Facial Contouring.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06783621 | Approved | Active |
Competing Products
13 competing products in Facial Contouring
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 85 |
| BOTOX®/VISTABEL® | AbbVie | Approved | 85 |
| Erenumab Prefilled Syringe | Amgen | Approved | 84 |
| Rapamune | Pfizer | Phase 1 | 32 |
| EMLA Cream | Sanofi | Phase 3 | 76 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 38 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 30 |
| Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) | Baxter | Phase 2 | 49 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 47 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |